Compare SHIM & NORD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | NORD |
|---|---|---|
| Founded | 1990 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Professional Services |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.9M | 95.5M |
| IPO Year | 2023 | 2005 |
| Metric | SHIM | NORD |
|---|---|---|
| Price | $3.24 | $2.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 60.6K | 15.7K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $492,844,000.00 | $3,346.00 |
| Revenue This Year | $1.41 | N/A |
| Revenue Next Year | $20.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.63 | N/A |
| 52 Week Low | $2.01 | $2.70 |
| 52 Week High | $6.76 | $5.28 |
| Indicator | SHIM | NORD |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 18.64 |
| Support Level | $2.89 | N/A |
| Resistance Level | $4.08 | $3.52 |
| Average True Range (ATR) | 0.21 | 0.57 |
| MACD | 0.07 | -0.19 |
| Stochastic Oscillator | 91.40 | 12.05 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.